Report Industry Investment Rating No information about the report industry investment rating is provided in the given content. Core Views - In October 2025, the intensity of convertible bond clause games may rise again. There are 47 convertible bonds whose non - downward - revision cooling periods end in October, significantly higher than August - September. And 18 convertible bonds' non - call cooling periods end, the second - highest this year [2][6]. - In terms of downward revision, among the convertible bonds whose downward - revision cooling periods end before October 2025, 6 convertible bonds worth over 2 billion yuan will start downward - revision counting. The proportion of convertible bonds proposing downward - revision announcements in 2025 is 12.5%. As the remaining term shortens and the equity market reaches a historical high, the probability of downward revision may increase. Since late August, the valuation of convertible bonds has declined, opening up price space for some games [2][8]. - Regarding call provisions, 21 convertible bonds end their call cooling periods before October 2025. Excluding Jingyuan Convertible Bond and Jinlun Convertible Bond, the parities of the rest are above 130 yuan as of September 19. With the continued prosperity of the equity market, the call pressure on individual bonds is not low. The convertible bond market scale is about to fall below 60 billion yuan, and the supply - demand contradiction persists, so the valuation may be strongly supported [2][13]. - As the equity market's rise slows down and the convertible bond valuation remains high, alpha returns from convertible bonds become more important. Investors may pay more attention to clause games. It is recommended to cherish the window period and select relevant targets from the clause + theme dimensions, especially those with certain demands and price space [2][14]. Summary by Directory 1. Attention to the upcoming wave of convertible bond clause games - In October 2025, there are 47 convertible bonds whose non - downward - revision cooling periods end, and 18 whose non - call cooling periods end, providing more clause - game opportunities compared to the same period in the past five years [2][6]. - In the downward - revision aspect, 6 large - scale convertible bonds will start downward - revision counting. The probability of downward revision may increase due to factors such as the short remaining term and high equity market position. Since late August, the valuation decline has created game space [2][8]. - For call provisions, 21 convertible bonds end their call cooling periods before October 2025. After exclusions, most have parities above 130 yuan. The call pressure is not low, and the valuation may be supported by the supply - demand contradiction [2][13]. 2. Market trends in a week - As of Friday's close, the Shanghai Composite Index closed at 3820.09, down 1.30% for the week, and the CSI Convertible Bond Index closed at 473.61, down 1.55%. The top - rising industries in the stock market are power equipment and new energy (+3.61%), coal (+3.59%), and consumer services (+3.52%), while the declining industries are comprehensive (-4.09%), banking (-4.09%), and non - ferrous metals (-3.93%) [15]. - No new convertible bonds were listed this week. 79 convertible bonds rose, accounting for 18%. The top - five gainers are Jingxing Convertible Bond (26.23%), Hengshuai Convertible Bond (21.84%), etc. 193 convertible bonds' conversion premium ratios increased, accounting for 45%. The top - five in valuation change are Jiete Convertible Bond (16.86%), Jingke Convertible Bond (14.61%), etc. [17]. 3. Important shareholders' convertible bond reduction - Companies that issued convertible bond reduction announcements this week are Jieneng Fengdian, Tianhao Energy, Jianfan Biology, and Nanjing Medicine [24]. - Many companies' major shareholders have reduced their holdings of convertible bonds, such as Zhejiang Yuesheng Group's reduction of Xingang Convertible Bond [25]. 4. Convertible bond issuance progress - The approval rhythm in the primary market has accelerated. Huichuangda (650 million yuan), Huaxiang Co., Ltd. (1.308 billion yuan), etc. are at the board - of - directors' proposal stage. Tonghe Technology (522 million yuan), Weike Precision (630 million yuan), etc. have passed the general meeting of shareholders. Shenyu Co., Ltd. (500 million yuan), Ruike Da (1 billion yuan) have passed the issuance review committee [26][27]. 5. Private EB project update - There is no progress update on private EB projects this week [28]. 6. Style & Strategy: The convertible bond market style was flat this week - All styles in the convertible bond market were not prominent. As of the last trading day of this week, the excess return of high - rated convertible bonds over low - rated ones was 0.10pct, that of large - amount convertible bonds over small - amount ones was - 0.22pct, and that of equity - biased convertible bonds over debt - biased ones was 0.03pct [30]. 7. One - week convertible bond valuation performance: Convertible bond valuation declined - The convertible bond market's 100 - yuan premium ratio fell to 28.66%, down 0.34% from the previous week, at the 84% historical percentile in the past six months and 92.4% in the past year. The median conversion premium ratio of all - caliber convertible bonds decreased by 1.4pct to 25.91%, and the market - value - weighted conversion premium ratio (excluding banks) decreased by 0.62pct to 39.45% [39]. - For equity - biased convertible bonds, the median conversion premium ratio was 9.71%, down 1.75pct from the previous week, at the 77.3% historical percentile in the past six months. For debt - biased convertible bonds, the median pure - debt premium ratio was 10.1%, down 1.91pct from the previous week, at the 73.9% historical percentile in the past six months [39]. - In terms of extreme pricing, as of the last trading day of this week, there was 1 convertible bond below par value, 0 below the debt floor, and 4 with a YTM greater than 3, at the 9.1%, 0%, and 10% historical percentiles since 2016 respectively [41]. - The median YTM of bank convertible bonds was - 2.68%, 4.56pct lower than the 3 - year AAA corporate bond yield. The median YTM of AA - to AA + debt - biased convertible bonds was - 1.24%, 3.36pct lower than the 3 - year AA corporate bond yield [45]. - The adjusted 100 - yuan premium ratio decreased. The adjusted 100 - yuan premium ratio considering various factors was 14.37%, at the 82.6% historical percentile in the past six months and 66.1% since 2018. The adjusted 100 - yuan premium ratio considering only the debt floor was at the 81.7% historical percentile in the past six months and 29.7% since 2018 [52].

Summary of Key Points Core Viewpoint - The company held its 2025 semi-annual performance briefing on September 18, 2025, to discuss its business strategies and performance metrics, focusing on digital transformation and new business models in the pharmaceutical industry [1]. Group 1: Company Performance and Strategy - The company aims for a minimum of 28% revenue growth in its emerging business for 2025 compared to 2024, with new business revenue reaching 851 million yuan in the first half of 2025 [2]. - The company reported that its SPD and "Internet+" businesses contributed approximately 3.3 billion yuan in revenue, accounting for about 12% of total revenue in the first half of 2025 [3]. - The company is actively managing its market value through share buybacks and strategic planning to enhance shareholder value and operational efficiency [3]. Group 2: Financial Metrics and Challenges - The company noted a significant divergence between net profit and operating cash flow, primarily due to an increase in accounts receivable, which the company plans to address through improved management [2]. - The company issued 4 billion yuan in short-term financing bonds to repay high-interest bank loans, indicating no immediate debt repayment pressure [3]. - The company’s gross margin for wholesale business is approximately 5.5%, while the gross margin for its emerging e-commerce business is around 15%, indicating higher profitability in new business models [5]. Group 3: Industry Outlook - The pharmaceutical distribution industry is expected to grow due to factors such as rising disposable income, increased health awareness, and an aging population, which will drive demand for healthcare and pharmaceutical products [4]. - The company is focusing on optimizing its economic structure and enhancing its supply chain capabilities to improve overall efficiency and profitability [4].

Core Insights - The company held a performance briefing for the first half of 2025, highlighting a wholesale business gross margin of approximately 5.5% and a higher gross margin of around 15% for its e-commerce business [1] - The strategic focus includes SPD business and "Internet+" initiatives in pharmaceuticals, covering B2B, B2C, O2O, special medical foods, and radioactive drugs [1] - Revenue from emerging businesses reached approximately 3.3 billion yuan, accounting for about 12% of total revenue in the first half of 2025 [1] Business Performance - The company has been actively cultivating its "Internet+" business alongside traditional pharmaceutical wholesale and retail operations [1] - New service models such as "Internet+ Pharmaceutical Services" and "Internet+ Traditional Chinese Medicine Services" have been launched, along with innovations in O2O and B2C e-commerce retail formats [1] - For the first half of 2025, emerging business revenue was 851 million yuan, achieving progress towards the target of at least 28% growth compared to 2024 [1]

| 证券代码：600713 | 证券简称：南京医药 | 编号：ls2025-120 | | --- | --- | --- | | 债券代码：110098 | 债券简称：南药转债 | | 南京医药股份有限公司 关于 2025 年半年度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 南京医药股份有限公司（以下简称"公司"）于2025年9月18日（星期四）通 过上海证券交易所上证路演中心线上召开了公司2025年半年度业绩说明会，现将 具体情况公告如下： 一、本次业绩说明会召开情况简介 2025年9月10日，公司对外披露《南京医药股份有限公司关于召开2025年半 年度业绩说明会的公告》（公告编号：ls2025-116）。公司于2025年9月18日（星 期 四 ） 上 午 9:30-11:30 ， 通 过 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/）以网络视频、图文展示及文字互动的方式召开了公 司2025年半年度业绩说明会，公司 ...

Group 1 - The Federal Reserve announced a 25 basis point interest rate cut, bringing the target range for the federal funds rate to 4.00%-4.25%, marking the first rate cut since December 2024 [2] - The European Union has implemented sanctions against Israel, including the partial suspension of trade-related aspects of the EU-Israel Association Agreement, in response to the situation in Gaza [3] - The Ministry of Commerce plans to conduct pilot projects for new consumption formats and models in approximately 50 cities to enhance quality consumption supply and stimulate economic growth [6] Group 2 - In August, China's fiscal revenue reached 148.198 billion yuan, with a year-on-year growth of 0.3%, marking the first positive growth in tax revenue this year [5] - The China Association of Automobile Manufacturers reported that domestic sales of new energy vehicles reached 1.171 million units in August, a year-on-year increase of 18.3%, with total sales for the first eight months reaching 8.088 million units, up 30.1% [10] - Vanke has undergone its largest organizational restructuring in recent years, adjusting its management structure to include 16 regional companies directly managed by headquarters [22] Group 3 - Dongfeng Group announced the establishment of a new joint venture company with a registered capital of 8.47 billion yuan, focusing on the Hummer brand and incorporating various intangible assets [23] - The Ministry of Industry and Information Technology is soliciting public opinions on mandatory national standards for safety requirements of intelligent connected vehicles [9] - The World Trade Organization predicts that AI could increase cross-border goods and services flow by nearly 40% by 2040, provided that policies are implemented to bridge the digital divide [21]

南京医药股份有限公司（以下简称"公司"）于近日收到控股股东南京新工投 资集团有限责任公司（以下简称"新工投资集团"）的通知，新工投资集团已于 2025 年 9 月 1 日至 2025 年 9 月 15 日期间通过上海证券交易所（以下简称"上交 所"）系统减持其持有的公司可转换公司债券（以下简称"可转债"）。现将具体情 况公告如下： 一、控股股东配售可转债情况 经中国证券监督管理委员会《关于同意南京医药股份有限公司向不特定对象发 行可转换公司债券注册的批复》（证监许可〔2024〕1736 号）核准，公司向不特 定对象发行可转债 10,814,910 张，每张面值为人民币 100 元（人民币，下同），发 行总额 108,149.10 万元。本次发行的可转债存续期限为自发行之日起六年（2024 年 12 月 25 日至 2030 年 12 月 24 日）。 证券代码：600713 证券简称：南京医药 编号：ls2025-119 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 关于控股股东减持公司可转换公司债券的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏， ...

| | | 债券代码：110098 债券简称：南药转债 南京医药股份有限公司关于公司及子公司 使用部分暂时闲置募集资金进行现金管理提前赎回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 南京医药股份有限公司（以下简称"公司"）于 2025 年 1 月 20-22 日召开 第九届董事会临时会议及第九届监事会临时会议，审议通过了《关于公司及子公 司使用部分暂时闲置募集资金进行现金管理的议案》，同意公司及子公司使用不 超过 7 亿元（含本数）暂时闲置募集资金进行现金管理，投资的产品品种为安全 性较高、流动性较好、风险较低的保本型理财产品。使用期限自公司董事会审议 通过之日起 12 个月内有效，上述额度在使用期限内可以滚动使用，到期后归还 至募集资金专户。详情请见公司于2025年1月23日对外披露的编号为ls2025-007 之《南京医药股份有限公司关于公司及子公司使用部分暂时闲置募集资金进行现 金管理的公告》。 1 公司于 2025 年 6 月 24 日赎回部分上述理财产品，收回本金 200 万元，并获 得理财收益 0.00 ...

Group 1 - The company Nanjing Pharmaceutical (600713.SH) has received a notification from New Investment Group regarding a reduction in holdings of "Nanjing Pharmaceutical Convertible Bonds" [1] - The reduction occurred between September 1, 2025, and September 15, 2025, totaling 1,081,500 bonds [1] - This reduction represents 10.00% of the total issuance of the convertible bonds [1]

Industry Overview - The pharmaceutical distribution industry serves as a critical link between pharmaceutical manufacturers and end consumers, characterized by a specialized division of labor [2][5] - The industry consists of upstream manufacturers producing various types of pharmaceutical products, including Western medicine, traditional Chinese medicine, medical devices, and chemical reagents [1] Cost Structure Analysis - The primary cost in the pharmaceutical distribution industry is sales cost, which includes product and raw material costs, accounting for approximately 95% of total sales costs, while other costs make up about 5% [5] Profitability Factors - Key drivers of profitability in the pharmaceutical distribution sector include sales scale and growth, gross margin levels, expense ratios, and inventory turnover [7] - Companies maintain stable gross margins through scale advantages and product structure adjustments, while controlling costs through refined management practices [7] Internet Integration - The integration of "Internet+" in the pharmaceutical distribution industry helps reduce costs and improve efficiency, allowing pharmaceutical companies to analyze order demands and pharmacies to manage inventory effectively [9] - Patients benefit from the ability to compare prices and brands online, facilitating informed purchasing decisions [9]

Market Overview - On September 12, the pharmaceutical commercial sector declined by 0.51%, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) leading with a 10.01% increase, closing at 31.31 [1] - Other notable performers included Haiwang Biological (000078) with a 2.69% increase and Runda Medical (603108) with a 1.30% increase [1] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 295 million yuan from institutional investors, while retail investors experienced a net outflow of 113 million yuan [2] - Major stocks like Seer Medical had a significant net inflow of 5.15 billion yuan from institutional investors, while retail investors showed a net outflow of 2.61 billion yuan [2]